Fighting Reverse Payments In The Drug Industry

Law360, New York (November 18, 2011, 2:10 PM EST) -- Patent litigation in the pharmaceutical industry is a fierce business. Typically, a brand-name drug manufacturer seeks to prevent a competitor from selling a generic version of the incumbent's drug that the latter believes infringes its hard-won intellectual property.

The strength of the relevant patents in these cases is often disputed, and, especially in light of the high costs of patent litigation, there is significant pressure on both parties to settle.

In some cases, the parties reach a settlement that provides for a compromise generic-entry date, as...
To view the full article, register now.